Trial Profile
A Randomized, Double-Blind, Phase 3b Proof-of-Concept Study to Evaluate the Efficacy and Safety of TAK-491 Compared to Placebo When Used in Combination With Metformin in Subjects With Hypertension and Type 2 Diabetes
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Azilsartan medoxomil (Primary) ; Metformin
- Indications Hypertension; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda
- 05 May 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 13 Nov 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 21 Feb 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.